Register
Login:
Share:
Email Facebook Twitter


EXCLUSIVE: Petro Metad go for broke with 6-well fully funded programme
EXCLUSIVE: Rockhopper #RKE tops Malcy's 2018 Interims Bucket List gain


Venn Life Sciences Share Price (VENN)



Share Price Information for Venn Life Sciences (VENN)


Share Price: 6.35Bid: 6.20Ask: 6.50Change: 0.00 (0.00%)No Movement on Venn Life
Spread: 0.30Spread as %: 4.84%Open: 6.35High: 6.35Low: 6.35Yesterday’s Close: 6.35

Venn Life Sciences Holdings Plc Ord 0.1P

Venn Life Sciences is listed in the FTSE AIM All-Share
Venn Life Sciences is part of the Health Care and Related Services sector






Share Price SpacerPrice
6.35
Share Price SpacerBid
6.20
Share Price SpacerAsk
6.50
Share Price SpacerChange
0%0.00
Share Price SpacerVolume
0
Share Price SpacerOpen
6.35
Share Price SpacerHigh
6.35
Share Price SpacerLow
6.35
Share Price SpacerClose
6.35
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 60.28m £3.83m 5,000

52 Week High 15.75 52 Week High Date 1-NOV-2017
52 Week Low 5.00 52 Week Low Date 13-APR-2018

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
0 0 0 -2.803 -2.27 0.00 0.00


London South East Users info for Venn Life Sciences




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

11-Jul-18
14:07:27
6.305
15,146
Sell* 
6.20
6.50
954.96
Trade Type:
Ordinary

11-Jul-18
12:17:07
6.47
20,000
Buy* 
6.20
6.50
1,294
Trade Type:
Ordinary

10-Jul-18
10:48:49
6.305
2,000
Sell* 
6.20
6.50
126.10
Trade Type:
Ordinary




View more Venn Life Sciences trades >>

Directors Deals for Venn Life Sciences (VENN)
Trade DateActionNotifierPriceCurrencyAmountHolding
31-Oct-16Buy
Trade Notifier Information for Venn Life Sciences Holdings
Allan Wood held the position of Chairman at Venn Life Sciences Holdings at the time of this trade.
 Allan Wood
21.5GBX65,000165000
31-Oct-16Buy
Trade Notifier Information for Venn Life Sciences Holdings
Allan Wood held the position of Chairman at Venn Life Sciences Holdings at the time of this trade.
 Allan Wood
21.73GBX165,000165000
19-Oct-15Notification of Holding
Trade Notifier Information for Venn Life Sciences Holdings
Kees Groen held the position of Executive Director at Venn Life Sciences Holdings at the time of this trade.
 Kees Groen
004780320
View more Venn Life Sciences directors dealings >>


AdJshares
Posts: 2,469
Opinion:No Opinion
Price:6.85
Amazing
28 Jun '18
An AGM. An RNS. Controversial motions denied. Not a post here or a share traded.

This is the most unloved interesting company on AIM
AdJshares
Posts: 2,469
Opinion:No Opinion
Price:6.85
VENN
28 Jun '18
I will be very interested to hear opinions of the vibe of the company from anybody that went to the AGM
AdJshares
Posts: 2,469
Opinion:No Opinion
Price:6.85
VENN
28 Jun '18
An AGM a resolution that looks like it was for getting hold of cash and yet no trades and no posts here. This must be the most unloved interesting company on a i m
rivaldo
Posts: 5,413
Opinion:Strong Buy
Price:7.15
Davy & Hybridan: positive coverage
17 May '18
From Hybridan this morning:

"@VennLifeScience (VENN) delivers a solid set of full year numbers. EBITDA more than doubling to �1.0m! In a very strong place to deliver on future growth.
@HybridianLLP"

And Davy now forecast �1.1m EBITDA for this year - not bad for a �4.3m m/cap company:

Https://www.davy.ie/research/public/article.htm?id=ST2_8081_1.xml.htm

"FY results: margin expansion drives EBITDA growth
May 17 2018
DAVY VIEW

Venn has started to benefit from business integration initiatives and infrastructure investments made in 2017. Greater operational efficiency has driven margin expansion and EBITDA growth. With a full service capability spanning early and late phase clinical projects, we think there is scope to develop new business lines and further increase margins. Additionally, management focus on M&A opportunities has the potential to accelerate growth. We forecast FY 2018 EBITDA of �1.1m and remain �Outperform�."
rivaldo
Posts: 5,413
Opinion:No Opinion
Price:7.15
Encouraging results today
17 May '18
The results looked mildly encouraging. Turnover of �17.8m and �1.0m underlying EBITDA is certainly indicative of potential relative to a �4.3m m/cap if VENN's management continue to simplify and transform the company as they have been doing.

Especially given they have �1.2m net cash to finance working capital and (from the tone of the narrative) an acquisition.

I'd largely written Integumen off almost entirely except as a very long-term possibility, but I do like the look of its potential acquisition/reverse. Let's hope it actually completes (there's a radio silence on this at present, which may be a good or bad thing) - if it does this could just have a material effect on VENN.

VENN's outlook is indeed difficult to discern, but perhaps there are clues for those looking for positives in the outlook given the focus on "improved underlying EBITDA", profitability and sunk investment costs which will hopefully pay off this year:

"During 2017 our focus has been on the delivered improved underlying EBITDA in the business through improved operational efficiencies. Additional investment in systems means that we now have both the expertise and infrastructure to profitably execute new business in scale and our focus is now on the generation of new business opportunities. We have invested significantly in business development and engaged creatively with clients to develop deeper, longer lasting partnerships and our pipeline of opportunities is healthy. We continue to see an increasing number of opportunities that require the full range of services now on offer in Venn."
View more share chat for Venn Life Sciences (VENN) >>







Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.